Precision BioSciences Insider Moves, CRISPR Pipeline & FDA Fast‑Track Outlook: What Investors & Clinicians Need to Know
Precision BioSciences insider activity shows routine RSU vesting, while CTX‑001’s Phase III safety data and FDA fast‑track status offer promising gene‑editing prospects for clinicians and investors.
4 minutes to read
